“Disease awareness campaigns…are an effective way for companies to sell a disease to sell a drug.“ Why did Americans pay more than $1.5 billion a year in 2016 alone for a drug that potentially does so little, and to treat a condition that many would not even consider to be a disease?
Why are Americans – both as patients and taxpayers – paying billions of dollars for a drug whose efficacy is so questionable that it’s not approved in the European Union, Australia or New Zealand?
Restasis is a blockbuster drug sold by Allergan to treat chronic dry eye. It has done $8.8 billion in U.S. sales between 2009 and 2015, including over $2.9 billion in public monies through Medicare Part D, according to a Dartmouth Institute.
Restasis and Allergan have been in the news lately due to the company’s novel legal strategy of transferring theirThis post was originally published on this site